C07K2317/565- Complementarity determining region.C07K2317/56- Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e.C07K2317/50- Immunoglobulins specific features characterized by immunoglobulin fragments.C07K2317/00- Immunoglobulins specific features.A61K2039/505- Medicinal preparations containing antigens or antibodies comprising antibodies.A61K39/00- Medicinal preparations containing antigens or antibodies.A61K- PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES.monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants monoclonal or polyclonal antibodies against material from animals or humans against growth factors against growth regulators A61P- SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS.A61- MEDICAL OR VETERINARY SCIENCE HYGIENE.monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes monoclonal or polyclonal antibodies against material from animals or humans Assignors: CETUS ONCOLOGYCORPORATION (FORMERLY CETUS CORPORATION) Application granted granted Critical Publication of US5877305A publication Critical patent/US5877305A/en Anticipated expiration legal-status Critical Status Expired - Lifetime legal-status Critical Current Links Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from US83196792A external-priority Application filed by Creative Biomolecules Inc, Chiron Corp filed Critical Creative Biomolecules Inc Priority to US08/356,786 priority Critical patent/US5877305A/en Assigned to CHIRON CORPORATION reassignment CHIRON CORPORATION MERGER (SEE DOCUMENT FOR DETAILS). Original Assignee Creative Biomolecules Inc Chiron Corp Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Ring Hermann Oppermann Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Expired - Lifetime Application number US08/356,786 Inventor James S. Google Patents DNA encoding biosynthetic binding protein for cancer markerÄownload PDF Info Publication number US5877305A US5877305A US08/356,786 US35678694A US5877305A US 5877305 A US5877305 A US 5877305A US 35678694 A US35678694 A US 35678694A US 5877305 A US5877305 A US 5877305A Authority US United States Prior art keywords sfv chain erbb polypeptide amino acid Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents US5877305A - DNA encoding biosynthetic binding protein for cancer marker US5877305A - DNA encoding biosynthetic binding protein for cancer marker
0 Comments
Leave a Reply. |